Angioedema-post COVID symptoms

Swathi Mukurala; Jahanavi Bandla; Swetha kappala; Swathi Mukurala; Jahanavi Bandla; Swetha kappala

doi:10.3934/Allergy.2023018

AIMS Allergy and Immunology

2023, Volume 7, Issue 4: 273-280. doi: 10.3934/Allergy.2023018

Previous Article Next Article

Mini review Special Issues

Angioedema-post COVID symptoms

Department of pharmaceutical Analysis, Vishnu Institute of pharmaceutical Education and Research, Narsapur, Medak, Telangana, India

Received: 07 September 2023 Revised: 25 November 2023 Accepted: 05 December 2023 Published: 19 December 2023

The non-respiratory symptoms associated with coronavirus disease 2019 (COVID-19) are being reported more frequently as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads throughout the world. Numerous dermatological issues have been connected to this viral infection. Angioedema has been reported by the patients post COVID. In this article, we discuss cases that have been reported in the medical literature and give a case study of angioedema that might be because of COVID-19 infection.
- cutaneous,
- angioedema (AE),
- COVID-19,
- allergy,
- immunoglobulin E
Citation: Swathi Mukurala, Jahanavi Bandla, Swetha kappala. Angioedema-post COVID symptoms[J]. AIMS Allergy and Immunology, 2023, 7(4): 273-280. doi: 10.3934/Allergy.2023018

Related Papers:

Abstract

The non-respiratory symptoms associated with coronavirus disease 2019 (COVID-19) are being reported more frequently as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads throughout the world. Numerous dermatological issues have been connected to this viral infection. Angioedema has been reported by the patients post COVID. In this article, we discuss cases that have been reported in the medical literature and give a case study of angioedema that might be because of COVID-19 infection.

Conflict of interest

The authors declare no conflicts of interest.

References

[1]	Khambholja K, Asudani D (2020) Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis 35: 101710. https://doi.org/10.1016/j.tmaid.2020.101710
[2]	Ceviker SA, Sener A, Yuksel C, et al. (2021) Acute urticaria with Angioedema in a patient with COVID-19 pneumonia: Favipiravir side effect or a rare cutaneous manifestation. JEM Case Rep 12: 65-67. https://doi.org/10.33706/jemcr.851107
[3]	Hassan K (2020) Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep 13: e236981. https://doi.org/10.1136/bcr-2020-236981
[4]	Recalcati S (2020) Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 34: e212-e213. https://doi.org/10.1111/jdv.16387
[5]	Watts MM, Maurer LE, Grammer LC, et al. (2022) Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine. Ann Allerg Asthma Im 128: 213-229. https://doi.org/10.1016/j.anai.2021.10.021
[6]	Memon RJ, Tiwari V (2023) Angioedema. StatPearls. Treasure Island: StatPearls Publishing.
[7]	Reshef A, Kidon M, Leibovich I (2016) The story of angioedema: from Quincke to bradykinin. Clin Rev Allerg Immu 51: 121-139. https://doi.org/10.1007/s12016-016-8553-8
[8]	Zipursky JS, Croitoru D (2021) Urticaria and angioedema associated with SARS-CoV-2 infection. CMAJ 193: E1390. https://doi.org/10.1503/cmaj.211087
[9]	Haq HN, Khan H, Chaudhry H, et al. (2022) Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions. J Natl Med Assoc 114: 601-612. https://doi.org/10.1016/j.jnma.2022.08.003
[10]	Kaplan AP (2008) Angioedema. World Allergy Organ J 1: 103-113. https://doi.org/10.1097/WOX.0b013e31817aecbe
[11]	Virdi G (2022) Dermal fillers and COVID-19: Angioedema with urticaria in a patient post COVID-19 infection. Cureus 14: e24461. https://doi.org/10.7759/cureus.24461
[12]	Ciaccio CE (2011) Angioedema: An overview and update. Mo Med 108: 354-357.
[13]	Kunder CA, St John AL, Abraham SN (2011) Mast cell modulation of the vascular and lymphatic endothelium. Blood 118: 5383-5393. https://doi.org/10.1182/blood-2011-07-358432
[14]	Elhag SAA, Ibrahim H, Abdelhadi S (2020) Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep 6: 1091-1094. https://doi.org/10.1016/j.jdcr.2020.07.042
[15]	Caballero T, Ferrer M, Guilarte M (2023) Classification and treatment of angioedema without wheals: a Spanish Delphi consensus. Am J Clin Dermatol 24: 135-141. https://doi.org/10.1007/s40257-022-00735-7
[16]	Cai Q, Yang M, Liu D, et al. (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6: 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007
[17]	Faraji N, Hosamirudsari H, Jalalabadi NZ, et al. (2022) Angioedema and urticaria as early presentations of a COVID-19 patient: a case report. Iran J Dermatol 25: 86-88.
[18]	Kesh S, Bernstein JA (2020) Isolated angioedema: A review of classification and update on management. Ann Allerg Asthma Im 129: 692-702. https://doi.org/10.1016/j.anai.2022.08.003
[19]	Nanda MK, Elenburg S, Bernstein JA, et al. (2015) Clinical features of pediatric hereditary angioedema. J Allergy Clin Immunol Pract 3: 392-395. https://doi.org/10.1016/j.jaip.2014.11.012
[20]	Bork K, Meng G, Staubach P, et al. (2006) Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 119: 267-274. https://doi.org/10.1016/j.amjmed.2005.09.064
[21]	Batarseh E, Kersten BP, Pinelo AC, et al. (2020) Angioedema in African American patients hospitalized for COVID-19. Am J Resp Crit Care 202: 1581-1583. https://doi.org/10.1164/rccm.202006-2223LE
[22]	Graziani A, Savrie C, Sama MG (2023) Acquired angioedema acute attack after administration of the Moderna COVID-19 (mRNA-1273) vaccine. Arch Bronconeumol 59: 165. https://doi.org/10.1016/j.arbres.2022.09.011
[23]	Gobert D, Paule R, Ponard D, et al. (2016) A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients. Medicine 95: e4363. https://doi.org/10.1097/MD.0000000000004363
[24]	Faraji N, Hosamirudsari H, Jalalabadi NZ, et al. (2022) Angioedema and urticaria as early presentations of a COVID-19 patient: A case report. Iran J Dermatol 25: 86-88.
[25]	Royer PY, Zayet S, Jacquin-Porretaz C, et al. (2021) Angioedema and COVID-19: a new dermatological manifestation?. Infect Dis Rep 13: 23-25. https://doi.org/10.3390/idr13010004
[26]	Cohen AJ, DiFrancesco MF, Solomon SD, et al. (2020) Angioedema in COVID-19. Eur Heart J 22: ehaa452. https://doi.org/10.1093/eurheartj/ehaa452
[27]	Elhag SAA, Ibrahim H, Abdelhadi S, et al. (2020) Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep 6: 1091-1094. https://doi.org/10.1016/j.jdcr.2020.07.042
[28]	Mohammed GF, Al-Dhubaibi MS, Atef L (2022) Cutaneous manifestations of coronavirus disease 2019: skin narratives and dialogues. J Clin Aesthet Dermatol 15: E77-E81.
[29]	Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochemi Pharmacol 78: 539-552. https://doi.org/10.1016/j.bcp.2009.04.029
[30]	Choudhury A, Mukherjee S (2020) In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol 92: 2105-2113. https://doi.org/10.1002/jmv.25987
[31]	Stone CA, Liu Y, Relling MV, et al. (2019) Immediate hypersensitivity to polyethylene glycols and polysorbates: More common than we have recognized. J Allergy Clin Immunol Pract 7: 1533-1540. https://doi.org/10.1016/j.jaip.2018.12.003
[32]	Zappia CD, Monczor F (2019) Therapeutic utility of glucocorticoids and antihistamines cotreatment. Rationale and perspectives. Pharmacol Res Perspect 7: e00530. https://doi.org/10.1002/prp2.530

Reader Comments

Your name:*

Email:*
© 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)